Drug Trial Radar · NCT00259610
Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)
Last checked: Nov 20, 2026Latest source record: Jul 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
755
Actual
Start
May 2004
Primary completion
Jun 2009
Study completion Jun 2009
Sponsor
- Lead sponsor
- University of Alabama at BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Amgen; Barr Laboratories; Pfizer
- First posted
- Nov 29, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to 1)to determine if it is better to treat all early RA patients with methotrexate in combination with hydroxychloroquine plus sulfasalazine or in combination with etanercept or reserve this treatment for patients who do not appropriately respond to methotrexate alone and 2) to determine which combination of methotrexate therapy is better
Conditions
- Rheumatoid Arthritis
Interventions
methotrexateDrug
varies
sulfasalazineDrug
varies
hydroxychloroquineDrug
varies
etanerceptDrug
varies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease Activity Score Erythrocyte Sedimentation Rate(DAS28-ESR)Time frame: Change of the Mean of DAS28-ESR between weeks 48 - 102.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.